Kim, A., Riedell, P., Ryan, C., Redd, R., Phinney, C., Mai, J., Pazienza, S., Bravo, C., Kats, V., Abdulkarim, S., Waisgerber, S., Merryman, R., Fisher, D., Ahn, I., Crombie, J., Odejide, O., LaCasce, A., Jacobson, C., Jacobsen, E., Parry, E., Qualls, D., Bessnow, A., Davids, M. S., Brown, J., Arnason, J., Leukam, M., Armand, P., Kline, J., Murakami, M. (2025). Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO). Blood. https://doi.org/10.1182/blood-2025-664